Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ICCMBullishCorporate Developmentsnews

Medium materiality6/10

IceCure expands ChoICE enrollment with Adventist Health Glendale milestone

Aug 6, 2026, 8:08 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive milestone signaling adoption progress and potential revenue upside, though near-term impact may be modest without readouts or earnings guidance. Similar biopharma/medtech updates with new clinical-site enrollments can trigger short-term moves, but material upside depends on enrollment speed and data.

AI summary

What happened, with direct paths to the underlying reporting

IceCure Medical announced Adventist Health Glendale becomes the first U.S. clinical site to enroll patients in the ChoICE post-marketing study for ProSense cryoablation in low-risk, elderly breast cancer. The trial targets 400 patients across 30 sites and aims to generate real-world data to support broader adoption and a dual pathway of study and commercial access.

Adventist Health Glendale is first U.S. site to enroll ChoICE patients.
ChoICE Study targets up to 400 patients across 30 sites.
ProSense cleared for 70+ with low-risk tumors ≤1.5 cm.
FDA marketing authorization for ProSense achieved in Oct 2025.
30 sites will be ChoICE study sites and active commercial sites.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.